[Sideroblastic anemia after prolonged linezolid therapy].

Abstract

Linezolid is an effective and well-tolerated antibiotic for the treatment of infections caused by Gram-positive pathogens. Some reports have shown that linezolid treatment for more than 2 weeks has been associated with reversible bone marrow suppression, especially thrombocytopenia and anemia. We encountered a case of sideroblastic anemia following prolonged linezolid therapy in a laryngeal cancer patient. He received linezolid therapy for multiple abscesses due to MRSA. Before treatment, the Hb level was 12.5 g/dl and then slowly decreased to 5.9 g/dl for 2 months during treatment. Ringed sideroblasts were detected in the bone marrow. Linezolid was discontinued and the Hb level was slowly increased. This case was considered to reflect a rare complication of linezolid therapy.

• Authors: Tsunayuki Kakimoto, Tomonori Nakazato, Reiko Miura, Hanako Kurai, Daisuke Yamashita, Yuko Sagara, Akaru Ishida
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 49 Issue 11 Pg. 1566-8 (Nov 2008) ISSN: 0485-1439 [Print] Japan
• PMID: 19047790 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Acetamides
• Anti-Infective Agents
• Oxazolidinones
• Linezolid

Topics

• Abscess (drug therapy)
• Acetamides (administration & dosage, adverse effects)
• Aged
• Anemia, Sideroblastic (chemically induced)
• Anti-Infective Agents (adverse effects)
• Humans
• Laryngeal Neoplasms
• Linezolid
• Male
• Methicillin-Resistant Staphylococcus aureus
• Oxazolidinones (administration & dosage, adverse effects)
• Staphylococcal Infections (drug therapy)